/l and on day +2, following 2 consecutive days of PBSC infusion, ANC = 0.5 × 10 9 /l with values for days +3, +4 and +6 being 0.4, 0.2 and 0.1 × 10 9 /l, respectively. Initial haemopoietic recovery occurred with ANC Ͼ1.0 × 10 9 /l by day +12 and 8.2 × 10 9 /l by day +13, when the platelet count was 32 × 10 9 /l. Platelets reached a maximum of 65 × 10 9 /l by day +18 but by day +24 graft failure had occurred, with a haemoglobin of 52 g/l, ANC 1.3 × 10 9 /l and reticulocytes Ͻ10 × 10 9 /l. A platelet count of 12 × 10 9 /l was recorded on day +28.
A second PBSCT was performed on day +35 after prior conditioning with cyclophosphamide 200 mg/kg, given in four divided doses over 4 days. 7.2 × 10 6 CD34 + cells/kg were reinfused and G-CSF (300 g/day) was given from day +2 to day +10 post-second PBSCT. An initial platelet increment of 18-125 × 10 9 /l was again observed but the evaluation of potential neutrophil increments following the second PBSCT was impeded by the confounding effects of prior dexamethasone (given as an anti-emetic) and cyclo- platelets Ͼ50 × 10 9 /l on day +13. Graphic illustration of blood count parameters in relation to treatment is shown in Figure 1a -c. One HLA matched platelet transfusion was required on day +9 post-second PBSC as prior HLA alloimmunisation had occurred despite the use of leucocyte useful temporary increments in both platelets, neutrophils and even erythrocytes can be obtained following the use of depletion filters.
We believe that this is the first reported case of syngeneic fresh G-CSF-mobilised PBSC in patients with SAA. The significant platelet increments would be of special value in PBSCT in SAA. The case confirms the potential for rapid and sustained engraftment characteristically associated with HLA alloimmunised patients. As recently reported, our case also illustrates the risk of graft failure in syngeneic G-CSF-mobilised PBSC grafts but it also illustrates that R 
